GLP-1 receptor agonists in children: safety, benefits, and long-term impact
Official title: The Benefits, Risks, and Long-term Impact of GLP-1 Receptor Agonists in Children
Funded at Indiana University Indianapolis · NIH-11357531 · Data updated 2026-11-12
A pediatric-focused study will track how GLP-1 receptor agonists affect kids aged 10–18 with obesity or type 2 diabetes over time, looking at safety and real-world outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | September 17, 2026 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $1,589,979 |
| NIH project number | 1R01HD122219-01 |
| Project ID | NIH-11357531 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children aged 10–18 years with obesity or type 2 diabetes who are potential candidates for GLP-1 receptor agonist therapy.
✕Less likely to help
Some children may not experience meaningful benefit or could experience adverse effects from GLP-1 receptor agonists.
What this research studies
This project uses real-world data from pediatric patients treated with GLP-1 receptor agonists to understand long-term safety, benefits, and development. It combines electronic health records and insurance data to build a framework for evaluating how these medicines work in children in everyday clinical settings. The study will identify which subgroups of children may benefit most or face higher risks, and it will look at clinical, psychological, and developmental outcomes. By focusing on data from Indiana and broader claims sources, researchers aim to inform safer, more effective use in the pediatric population.
Why it matters
Potential benefit: If successful, the findings could guide safer prescribing and better long-term outcomes for children treated with GLP-1 receptor agonists.
How similar studies have gone: Prior short-term pediatric data show promise, but comprehensive long-term real-world evidence in children remains limited.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Bian, Jiang — Indiana University Indianapolis
- Study coordinator: Bian, Jiang
Related research
Other NIH-funded projects on the same topics.
-
Understanding how GLP-1 drugs affect energy use in brittle diabetes
This grant looks at how GLP-1 receptor drugs change how the body handles sugar and fats, beyond lowering blood sugar or appetite, to help people with brittle diabetes.
-
GLP-1 receptor drugs and heart-brain health in diabetes and Alzheimer’s risk
A Duke-led study will explore how GLP-1 receptor medicines and exercise affect brain and heart health in models prone to diabetes and Alzheimer’s risk.
-
GLP-1 medicines to improve heart, kidney, and metabolic health for people with HIV and type 2 diabetes
A real-world study will look at how GLP-1 receptor agonists affect heart and kidney health and lifetime costs for people living with HIV and type 2 diabetes.
-
Lifestyle plan to protect muscle and heart health for adults with obesity using GLP-1 medications
A real-world trial tests a combined nutrition and resistance-training program versus standard care for adults starting GLP-1 weight loss drugs to preserve lean mass and cardiovascular health.
-
Pre-pregnancy GLP-1 Medication Use and Stopping It: Effects on Blood Sugar and Pregnancy Outcomes
This project looks at how using GLP-1–based weight loss medicine before pregnancy and stopping it before trying to conceive affects blood sugar and pregnancy health.
-
Ways to keep weight off after stopping GLP-1 weight-loss meds
This project tests simple strategies to help adults who have obesity keep weight off after stopping high-dose GLP-1 medicines.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.